TY - JOUR
T1 - European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part IV: deep brain stimulation
AU - Szejko, N.
AU - Worbe, Y.
AU - Hartmann, A.
AU - Visser-Vandewalle, V.
AU - Ackermans, L.
AU - Ganos, C.
AU - Porta, M.
AU - Leentjens, A.F.G.
AU - Mehrkens, J.H.
AU - Huys, D.
AU - Baldermann, J.C.
AU - Kuhn, J.
AU - Karachi, C.
AU - Delorme, C.
AU - Foltynie, T.
AU - Cavanna, A.E.
AU - Cath, D.
AU - Muller-Vahl, K.
N1 - Funding Information:
JM has received speaker’s honoraria from Abbott, Medtronic, Boston Scientific and BrainLab. CG received research grants from the VolkswagenStiftung (Freigeist Fellowship) and the German Parkinson Society and was also supported by the Deutsche Forschungsgemeinschaft (GA2031/1-1 and GA2031/1-2) and Actelion Pharmaceuticals. He also received financial support/honoraria to speak at meetings by Actelion pharmaceuticals and as ad hoc advisory board for Lundbeck. CD has been awarded travel grants from Medtronic, Boston Scientific and Merz Pharma. AFGL received a research grant from the Michael J Fox Foundation and royalties from Springer media. TF received honoraria for talks sponsored by Boston scientific, Bial and Profile Pharma. He also was funded with grants from NIHR, Innovate UK, Cure Parkinson’s trust, Michael J Fox foundation, John Black Charitable Foundation, Van Andel Institute and Defeat MSA. JK has received financial support for Investigator initiated trials from Medtronic GmbH and grants from the German Research Foundation (KU2665/1-2) and the Marga and Walter Boll Foundation. KMV has received financial or material research support from EU (FP7-HEALTH-2011 No. 278367, FP7-PEOPLE-2012-ITN No. 316978) DFG: GZ MU 1527/3-1 and GZ MU 1527/3-2, BMBF: 01KG1421, National Institute of Mental Health (NIMH), Tourette Gesellschaft Deutschland e.V. Else-Kröner-Fresenius-Stiftung, GW pharmaceuticals, Almirall Hermal GmbH, Abide Therapeutics, and Therapix Biosiences. She has received consultant's honoraria from Abide Therapeutics, Boehringer Ingelheim International GmbH, Bionorica Ethics GmbH, CannaMedical Pharma GmbH, Canopy Grouth, Columbia Care, CTC Communications Corp., Demecan, Eurox Deutschland GmbH, Global Praxis Group Limited, IMC Germany, Lundbeck, Sanity Group, Stadapharm GmbH, Synendos Therapeutics AG, and Tilray. She is an advisory/scientific board member for CannaMedical Pharma GmbH, Bionorica Ethics GmbH, CannaXan GmbH, Canopy Growth, Columbia Care, IMC Germany, Leafly Deutschland GmbH, Sanity Group, Syqe Medical Ltd., Therapix Biosciences Ltd., and Wayland Group. She has received speaker’s fees from Aphria Deutschland GmbH, Almirall, Cogitando GmbH, Emalex, Eurox Deutschland GmbH, Ever pharma GmbH, Meinhardt Congress GmbH, PR Berater, Spectrum Therapeutics GmbH, Takeda GmbH, Tilray, Wayland Group. She has received royalties fromDeutsches Ärzteblatt, Der Neurologie und Psychiater, Elsevier, Medizinisch Wissenschaftliche Verlagsgesellschaft Berlin, and Kohlhammer. She served as a guest editor for Frontiers in Neurology on the research topic “The neurobiology and genetics of Gilles de la Tourette syndrome: new avenues through large-scale collaborative projects”, is an associate editor for “Cannabis and Cannabinoid Research” and an Editorial Board Member of “Medical Cannabis and Cannabinoids” und “MDPI-Reports” and a Scientific board member for “Zeitschrift für Allgemeinmedizin”. AH has received consultancy honoraria from Lundbeck and Noema Pharma. He has received research grants from the Association Française pour le Syndrome Gilles de la Tourette (AFSGT). DC received grant from the EU (TS EUROTRAIN), grant nr. 316978), several grants from ZONMW and MAGW (the Netherlands), from TSA-USA (2008), from Sunovion (DS028 (2019). From Espria fonds, Drenthe, the Netherlands. She has received speakers’ fees from ECNP, Psyfar, Benecke, Pfizer. JCB and VVV area funded by the Deutsche Forschungsgemeinschaft, German Research Foundation (Project-ID: 431549029–SFB 1451). All other authors have no conflicts to declare.
Publisher Copyright:
© 2021, The Author(s).
PY - 2022/3
Y1 - 2022/3
N2 - In 2011 the European Society for the Study of Tourette Syndrome (ESSTS) published its first European clinical guidelines for the treatment of Tourette Syndrome (TS) with part IV on deep brain stimulation (DBS). Here, we present a revised version of these guidelines with updated recommendations based on the current literature covering the last decade as well as a survey among ESSTS experts. Currently, data from the International Tourette DBS Registry and Database, two meta-analyses, and eight randomized controlled trials (RCTs) are available. Interpretation of outcomes is limited by small sample sizes and short follow-up periods. Compared to open uncontrolled case studies, RCTs report less favorable outcomes with conflicting results. This could be related to several different aspects including methodological issues, but also substantial placebo effects. These guidelines, therefore, not only present currently available data from open and controlled studies, but also include expert knowledge. Although the overall database has increased in size since 2011, definite conclusions regarding the efficacy and tolerability of DBS in TS are still open to debate. Therefore, we continue to consider DBS for TS as an experimental treatment that should be used only in carefully selected, severely affected and otherwise treatment-resistant patients.
AB - In 2011 the European Society for the Study of Tourette Syndrome (ESSTS) published its first European clinical guidelines for the treatment of Tourette Syndrome (TS) with part IV on deep brain stimulation (DBS). Here, we present a revised version of these guidelines with updated recommendations based on the current literature covering the last decade as well as a survey among ESSTS experts. Currently, data from the International Tourette DBS Registry and Database, two meta-analyses, and eight randomized controlled trials (RCTs) are available. Interpretation of outcomes is limited by small sample sizes and short follow-up periods. Compared to open uncontrolled case studies, RCTs report less favorable outcomes with conflicting results. This could be related to several different aspects including methodological issues, but also substantial placebo effects. These guidelines, therefore, not only present currently available data from open and controlled studies, but also include expert knowledge. Although the overall database has increased in size since 2011, definite conclusions regarding the efficacy and tolerability of DBS in TS are still open to debate. Therefore, we continue to consider DBS for TS as an experimental treatment that should be used only in carefully selected, severely affected and otherwise treatment-resistant patients.
KW - Tics
KW - Tourette syndrome
KW - Deep brain stimulation
KW - Treatment
KW - Guidelines
KW - European Society for the Study of Tourette Syndrome (ESSTS)
KW - GLOBUS-PALLIDUS INTERNUS
KW - QUALITY-OF-LIFE
KW - TERM-FOLLOW-UP
KW - LONG-TERM
KW - DOUBLE-BLIND
KW - THALAMIC-STIMULATION
KW - PATIENT SELECTION
KW - NUCLEUS-ACCUMBENS
KW - ASSESSMENT RECOMMENDATIONS
KW - TRIAL
U2 - 10.1007/s00787-021-01881-9
DO - 10.1007/s00787-021-01881-9
M3 - (Systematic) Review article
C2 - 34605960
SN - 1018-8827
VL - 31
SP - 443
EP - 461
JO - European Child & Adolescent Psychiatry
JF - European Child & Adolescent Psychiatry
IS - 3
ER -